Products

BRCA Tumor MASTR Plus - Multiplicom

Mutations in the BRCA1 and BRCA2 from tumor tissues

BRCA Tumor MASTR™ Plus (RUO) is a molecular assay for the identification of mutations in the coding regions of the BRCA1 and BRCA2 genes in cancer patients and is compatible both for the detection of germline mutations as well as mutations in tumor samples.

BRCA1 and BRCA2 can show both germline and somatic mutations. Germline mutations are the most common cause for familial breast and ovarian cancer predisposition. In tumors, mutations in BRCA1 and BRCA2 have prognostic value but also predict the response to molecular targeted therapy. PARP inhibitors (PARPi) exploit the vulnerability of cancer cells that is caused by mutations in BRCA1 and BRCA2. BRCA Tumor MASTR Plus (RUO) can thus be used as a criterion for the treatment with the PARPi Lynparza, which is approved for high-grade serous ovarian cancer patients with BRCA1 or BRCA2 mutations in the tumor.

The excellent functional characteristics make BRCA Tumor MASTR Plus (RUO) a single test that works both for the detection of germline and tumor mutations in BRCA1 and BRCA2. Additionally, the MASTR Plus protocol is compatible with the common Next-Generation Sequencing platforms.

Show more

http://www.multiplicom.com/product/brca-tumor-mastr-plus-0
Petra Kupková

Sales manager

Petra

Kupková

+420 731 426 051

Send Message

Related products

These kits are to be used for the second PCR step to incorporate barcoding and adaptors required for 454 GS Junior or 454 GS FLX instruments (Roche).

show detail

The drMID for Illumina NGS systems is developed for incorporating molecular identifiers (MIDs) and adaptors into amplicons of MASTR-based assays, enabling Next-Generating Sequencing (NGS) in 2 directions (dual read) on all Illumina NGS platforms.

show detail

These kits are to be used in combination with the MASTR™ assays.

show detail

The kits are to be used in combination with the MASTR™ assays for the second PCR to incorporate barcoding and adaptors required for the Ion PGM™ System.

show detail

This assay is to be used in combination with the MASTR assays, for applications on

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey